It is a widely understood that androgen deprivation therapy (ADT) causes adverse side effects and events. Some researchers believe that the ADT-induced alterations in lipid and glucose metabolism may be race-dependent. To evaluate this concern the researchers recruited Japanese men with newly diagnosed prostate cancer who also underwent at least one year of ADT. They [...]
Malecare announces the addition of our latest and informative teleconference about Immunotherapy and Advanced Prostate Cancer. Joining me in the conference is Dr. Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member [...]
Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will often have debilitating pain that impacts every aspect of their daily functioning thus significantly diminishing their quality of life (QoL). Finding the best drug or treatment to control the pain will allow men to have a more complete and fulfilling life as well as [...]
Circulating tumor cells (CTCs) is an area we will continue to hear more about as their importance to our understanding prostate cancer continues to increase. CTCs show the movement of cancer cells though the body. It is believed that these CTCs are the method that cancer uses to spread through our body (metastasize). Measuring the [...]
Last October at the European Cancer Congress 2013 there was a release of data from a phase 3 study of Ipilimumab (CA 184-043) that showed that it might be effective in treating castration-resistant prostate cancer in men who have a low burden of disease; however it failed to show at the required 95% confidence level [...]